The Pharma Letter4 天
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
BioSpace5 天
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
搜狐17 天
Alector股价大跌5.23%：市场反应揭示了什么？
Alector的产品管道中包括多种候选药物，例如AL001、AL002、AL003和AL101，正处于临床试验阶段。 在生物技术行业，创新是生死攸关的问题，而市场的敏感 ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
FierceBiotech5 天
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
Alector停止阿尔茨海默病试验未达主要终点
南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.
Morningstar6 天
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early ...
The instances of ARIA were primarily seen in participants treated with AL002. “We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer’s disease and remain ...
高盛维持对Alector的卖出评级，目标价4美元，关注阿尔茨海默病研究
周二，高盛重申了对Alector Inc. (NASDAQ:ALEC)股票的卖出评级，维持4.00美元的目标价。关注点集中在即将公布的INVOKE-2研究的第二阶段结果，该研究正在评估Alector的AL002用于治疗阿尔茨海默病。高盛对该资产和研究提供了深入的背景分析，预览了可能的结果，并讨论了这些结果对公司估值的潜在影响。